预约演示
Ascletis drops FXR agonistFXR agonist after disappointing mid-stage PBC data
2024-04-03
临床2期临床结果上市批准
Ascletis Pharma is pulling the plug on its farnesoid X receptor (FXR) agonist ASC42, which was being developed across multiple indications. The move follows an analysis of Phase II efficacy and safety data in primary biliary cholangitis (PBC), revealing that ASC42 "did not show competitiveness" compared to other drug candidates currently in late-stage testing for the same indication.
In addition to halting the PBC programme, Ascletis is also terminating further clinical studies of ASC42 as part of a combination regimen for metabolic dysfunction-associated steatohepatitis (MASH), formerly referred to as non-alcoholic steatohepatitis (NASH), and as a monotherapy for hepatitis B virus infection.
Speed work on other MASH assets
Ascletis says the savings generated from discontinuing the planned clinical trials will be redirected towards accelerating development of two other potential MASH candidates, ASC41 and ASC40, as well as supporting the Chinese biotech's in-house discovery efforts.
ASC41 is a once-daily oral THRβ agonist that led to significant reductions in fat content in patients with biopsy-confirmed MASH, according to interim Phase II results unveiled earlier this year. The compound is in the same class as Madrigal Pharmaceuticals' Rezdiffra (resmetirom), which became the first approved MASH treatment when US regulators signed off on it last month.
Ascletis' drug has also been at the centre of a dispute with Viking Therapeutics, which claimed that ASC41 is based on stolen trade secrets revolving around its own THRβ drug, VK2809.
Meanwhile, Asceltis said its FASN inhibitorFASN inhibitor ASC40, also known as denifanstat, achieved statistically significant results for both MASH resolution and fibrosis improvement in a Phase IIb study of NASH patients with stage 2 or 3 fibrosis after 52 weeks of treatment. ASC40 is also in late-stage development as an acne treatment, and in combination with bevacizumab for patients with recurrent glioblastoma.
The company's most advanced drug candidate is ASC22, a subcutaneously injected PD-L1 antibody currently in Phase II as a potential functional cure for both chronic hepatitis B and HIV.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。